VIVUS (NASDAQ: VVUS) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares VIVUS and Chiasma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|VIVUS||$133.40 million||0.55||$67.14 million||$0.31||2.25|
VIVUS has higher revenue and earnings than Chiasma. Chiasma is trading at a lower price-to-earnings ratio than VIVUS, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and target prices for VIVUS and Chiasma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
36.9% of VIVUS shares are held by institutional investors. Comparatively, 50.4% of Chiasma shares are held by institutional investors. 4.4% of VIVUS shares are held by company insiders. Comparatively, 3.8% of Chiasma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares VIVUS and Chiasma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
VIVUS has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
VIVUS beats Chiasma on 7 of the 9 factors compared between the two stocks.
VIVUS Company Profile
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Chiasma Company Profile
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
What are top analysts saying about VIVUS Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VIVUS Inc. and related companies.